TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18762508
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose solution (1 mL of 25% sucrose solution)
Study: 15785924
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Study: 15785924
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched control group), applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Study: 7738792
Drug: Enoximone bolus
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone bolus single dose (0.25‐2.0 mg/kg)
Study: 7738792
Drug: Enoximone continuous
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone continuous infusion (4‐h)
Study: 7738792
Drug: Enoximone bolus
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone bolus multiple doses (four consecutive doses at 3‐h intervals)
Study: 2028004
Drug: Nonionic (low‐osmolality)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic (low‐osmolality) contrast agents
Study: 6797454
Drug: MR 1268
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR 1268 2.5 mg
Study: 6797454
Drug: MR 1268
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR 1268 5 mg
Study: 6797454
Drug: MR 1268
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR 1268 10 mg
Study: 6797454
Drug: MR 1268
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR 1268 20 mg
Study: 28415943
Drug: 20 mL of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% bupivacaine (Group B, n = 30)
Study: 28415943
Drug: 20 mL of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% levobupivacaine (Group L, n = 30)
Study: 25903217
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol self-administration (up to a maximum BAC of 160 mg% in study 1 and 120 mg% in study 2)
Study: 23574969
Drug: Etanercept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (10 mg)
Study: 16687482
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physiotherapy and brace
Study: 9165176
Drug: Moderate aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate aerobic exercise added to medical antihypertensive therapy
Study: 9165176
Drug: Medical antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical antihypertensive therapy (indapamide +/- verapamil +/- enalapril)
Study: 21620416
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 as add-on therapy to subcutaneous interferon β-1a
Study: 21620416
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as add-on therapy to subcutaneous interferon β-1a
Study: 18980263
Drug: Caffeine (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.75 mg/kg) three times daily for four consecutive weeks
Study: 14583369
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 to 10 mg once daily
Study: 14583369
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 to 25 mg twice daily
Study: 8664034
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (daily oral treatment with 30 mg of TAM and 600 mg of FT)
Study: 8664034
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (daily oral treatment with 30 mg of TAM)
Study: 8664034
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (daily oral treatment with 30 mg of TAM and 3 g of PSK)
Study: 8664034
Drug: Regimen D
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen D (daily oral treatment with 600 mg of FT)
Study: 8664034
Drug: Regimen E
Normalized name: ASPIRIN 325 mg ORAL TABLET, COATED [Bayer Aspirin Regimen enteric coated]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen E (daily oral treatment with 3 g of PSK)
Study: 27555486
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural steroid administration (Group S, n=48) with 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.
Study: 27555486
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural local anesthetic administration (Group L, n=50) with 10 mL 0.25% bupivacaine.
Study: 26602290
Drug: Lactoferrin‐fortified formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin‐fortified formula milk group (FG, containing lactoferrin 38 mg/100 g milk)
Study: 24433430
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (methotrexate/ciclosporin/prednisolone)
Study: 24433430
Drug: Monotherapy (methotrexate)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (methotrexate)
Study: 19056555
Drug: Control bar
Normalized name: SALICYLIC ACID 2 g in 100 g TOPICAL SOAP [Blemish Control Bar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control bar containing 0.3 g beta-glucan from 6.8 g oats
Study: 19056555
Drug: Bar with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar with an additional 0.9 g beta-glucan from 8.0 g barley
Study: 19056555
Drug: Bar with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar with 8 g FOS
Study: 19056555
Drug: Bar with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar with 0.9 g beta-glucan + 8 g FOS
Study: 19056555
Drug: Bar with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar with 0.9 g beta-glucan
Study: 18158075
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 µg BID
Study: 18158075
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine QD (titrated targeting FSG < or =5.6 mmol/L)
Study: 15079179
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1 mg/kg)
Study: 15079179
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (2 mg)
Study: 15079179
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral and nebulized)
Study: 11586485
Drug: gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil 600 mg twice daily for 4 months
Study: 11586485
Drug: simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 10 mg daily for 4 months
Study: 11586485
Drug: gemfibrozil and
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil and simvastatin (both treatments)
Study: 11586485
Drug: simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin treatment
Study: 9884813
Drug: dyed aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: dyed aqueous nasal spray
Study: 9884813
Drug: vigorous inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: vigorous inhalation while spraying
Study: 913863
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oxprenolol every six hours during marathon bowling
Study: 913863
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg oxprenolol 60 minutes prior to shooting matches
Study: 27612487
Drug: Individual feedback
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual feedback group (n = 36) that received a daily alarm and a weekly medication adherence feedback report
Study: 27612487
Drug: Partner feedback
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partner feedback group (n = 54) that received an alarm and a weekly feedback report shared with a friend, family member, or peer
Study: 27612487
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 36) that received a pill‐monitoring device with no alarms or feedback
Study: 23135345
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg/day with vitamin D
Study: 21596994
Drug: Pregabalin 200
Normalized name: pregabalin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 200 mg
Study: 9291170
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg daily for 2 days administered every 4 weeks for 24 weeks
Study: 3092099
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride (Trexan) at 300 mg dosage
Study: 9000837
Drug: Capsules (A)
Normalized name: Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules (A)
Study: 9000837
Drug: Tablets (C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (C)
Study: 23261129
Drug: Aripiprazole adjunctive
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole adjunctive to lithium/valproate
Study: 23261129
Drug: Aripiprazole adjunctive
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole adjunctive to lamotrigine
Study: 23261129
Drug: Aripiprazole adjunctive
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole adjunctive to mood stabilizers
Study: 23261129
Drug: Mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood stabilizer monotherapy
Study: 11408333
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation in a temporal forced choice paradigm
Study: 25006070
Drug: Ractopamine hydrochloride
Normalized name: ractopamine hydrochloride
DrugBank: Ractopamine (DB11541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ractopamine hydrochloride (RAC; 5 mg/kg)
Study: 22437659
Drug: Arthroscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic treatment followed by exercise therapy for 2 months
Study: 20552353
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using Photofrin, HPD, ALA, or Foscan
Study: 20552353
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) for laryngeal cancers
Study: 20552353
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) compared to conventional therapies
Study: 16325020
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined regimen: combined oestrogen/progestogen skin patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day)
Study: 16325020
Drug: Interrupted regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted regimen: oestrogen-only patches (releasing 80 microg estradiol/day) for 4 days followed by combined oestrogen/progestogen patches (releasing continuous 50 microg estradiol and 20 microg levonorgestrel/day) for 3 days
Study: 2050424
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg three times daily)
Study: 2050424
Drug: Trimethoprim-sulfamethoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (960 mg three times daily)
Study: 27862066
Drug: AFXL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFXL treatment
Study: 26399603
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy for the first 4 weeks
Study: 22730470
Drug: Lesogaberan 60
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 60 mg twice daily
Study: 22730470
Drug: Lesogaberan 120
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 120 mg twice daily
Study: 22730470
Drug: Lesogaberan 180
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 180 mg twice daily
Study: 22730470
Drug: Lesogaberan 240
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 240 mg twice daily
Study: 16737869
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (EM) 10 mg/kg every 6 hours for 2 days, followed by 4 mg/kg every 6 hours for another 5 days
Study: 11444418
Drug: Enteric-coated garlic
Normalized name: GARLIC OIL TAB,EC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated garlic powder tablets with 9.6 mg allicin-releasing potential
Study: 9120818
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension without sodium lauryl sulfate (SLS)
Study: 9120818
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension with sodium lauryl sulfate (SLS)
Study: 9120818
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil tablet formulation
Study: 31962179
Drug: Pre-ICU cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ICU cold intravenous (i.v.) fluids
Study: 31962179
Drug: No pre-ICU
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-ICU cold intravenous (i.v.) fluids
Study: 23343363
Drug: Client-centred occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centred occupational therapy (OT)
Study: 18158312
Drug: Gelatin solution
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin solution
Study: 18158312
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution
Study: 14521738
Drug: Diltiazem infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem infusion (0.1 mg/kg/h)
Study: 9407509
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lisinopril (group 1)
Study: 9407509
Drug: No ACE
Normalized name: Amino Acetic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACE inhibitor therapy (group 2)
Study: 2862808
Drug: Atracurium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 2.5 mg
Study: 2862808
Drug: Atracurium 5
Normalized name: cisatracurium 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 5 mg
Study: 2862808
Drug: Fazadinium 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium 3.75 mg
Study: 29321141
Drug: Multidisciplinary, aerobic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary, aerobic, motor-cognitive and intensive rehabilitation treatment (MIRT) for 4 weeks
Study: 25378424
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of autologous bone marrow mononuclear stem cells (BMSCs)
Study: 17651149
Drug: Symptomatic steroid-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic steroid-free asthmatics
Study: 16092896
Drug: Experiential cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential cognitive therapy (ExCT), 4 sessions
Study: 16092896
Drug: Experiential cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential cognitive therapy (ExCT)
Study: 12005142
Drug: Brånemark System
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark System implants
Study: 2194004
Drug: Iopanoic acid
Normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopanoic acid (1 gm daily for 21 days)
Study: 28740376
Drug: FP/FORM 500/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/FORM 500/20 µg
Study: 28740376
Drug: FP/FORM 250/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/FORM 250/10 µg
Study: 28740376
Drug: FP/FORM 500/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/FORM 500/20 µg and FP/FORM 250/10 µg
Study: 28740376
Drug: FP/FORM 500/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/FORM 500/20 µg, FP/FORM 250/10 µg, FORM
Study: 23386653
Drug: Prednisolone (PRED)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PRED) 7.5 mg once daily (n = 12)
Study: 23386653
Drug: Prednisolone (PRED)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PRED) 30 mg once daily (n = 12)
Study: 19710500
Drug: laromustine and
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: laromustine and high-dose cytarabine (HDAC)
Study: 19710500
Drug: high-dose cytarabine/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose cytarabine/placebo
Study: 17240287
Drug: 800 mcg
Normalized name: Biotin 800 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mcg daily oral folic acid
Study: 15566917
Drug: Fluid balance
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid balance and volume administered on postoperative day 2
Study: 18621791
Drug: Bimatoprost once
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost once daily
Study: 12488264
Drug: Bimatoprost twice
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost twice daily
Study: 496555
Drug: Drug-free state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free state serum calcium levels in patients with EPS
Study: 496555
Drug: Drug-free state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free state serum magnesium levels in patients with EPS
Study: 496555
Drug: Neuroleptic dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic dosage
Study: 496555
Drug: Serum calcium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum calcium and magnesium levels during neuroleptic treatment
Study: 31897708
Drug: NAPP application
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAPP application into the pockets, adjunctive to NSPT
Study: 21882343
Drug: treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with anti-miR-21
Study: 19122476
Drug: HX575 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX575 (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Study: 19122476
Drug: Comparator epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator epoetin alfa (100 IU/kg body weight, subcutaneous, 3 times weekly for 4 weeks)
Study: 17525168
Drug: Fosaprepitant 115
Normalized name: fosaprepitant 115 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 115 mg
Study: 17525168
Drug: Fosaprepitant up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant up to 150 mg (1 mg/mL)
Study: 16113431
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) such as fluticasone
Study: 8036221
Drug: Multimodality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality treatment using oliphenum, prednisolone or their combination
Study: 28843241
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with intravenous sodium glycerophosphate (Glycophos) 1.5 mmol/kg/day
Study: 21129944
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 μg/nasal cavity twice daily
Study: 19001519
Drug: Individualized GH
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized GH dose (17-100 microg/kg.d)
Study: 19001519
Drug: Standard GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GH dose (43 microg/kg.d)
Study: 16730488
Drug: Valdecoxib, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib, 40 mg, once a day for 5 days